Fast Five Quiz: Type 2 Diabetes and Cerebrovascular Disease

Romesh Khardori, MD, PhD, FACP


April 27, 2022

Numerous studies have suggested that GLP1 receptor agonists may reduce the risk for stroke in patients with type 2 diabetes. One such study, the SUSTAIN trial, examined the cardiovascular outcomes of semaglutide and demonstrated a 39% reduction of nonfatal stroke and 26% reduction of nonfatal myocardial infarction. The beneficial actions of GLP1 receptor agonists were later confirmed with systemic reviews and meta-analyses. In addition, a recent study comparing GLP1 receptor agonists and SGLT2 inhibitors concluded that GLP1 receptor agonist reduced the risk for stroke and peripheral artery disease, further supporting previous findings, whereas heart failure and mortality were reduced with SGLT2 inhibitors.

High-dose insulin and sulfonylureas are among the glucose-lowering agents that may be associated with an increased risk for stroke.

Learn more about type 2 diabetes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.